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Abstract
In an effort to expand the worldwide pool of available medical countermeasures (MCM) against
radiation, the PEGylated G-CSF (PEG-G-CSF) molecules Neulasta and Maxy-G34, a novel PEG-
G-CSF designed for increased half-life and enhanced activity compared to Neulasta, were
examined in a murine model of the Hematopoietic Syndrome of the Acute Radiation Syndrome
(H-ARS), along with the lead MCM for licensure and stockpiling, G-CSF. Both PEG-G-CSFs
were shown to retain significant survival efficacy when administered as a single dose 24hr post-
exposure, compared to the 16 daily doses of G-CSF required for survival efficacy. Furthermore,
0.1 mg kg−1 of either PEG-G-CSF effected survival of lethally-irradiated mice that was similar to
a 10-fold higher dose. The one dose/low dose administration schedules are attractive attributes of
radiation MCM given the logistical challenges of medical care in a mass casualty event. Maxy-
G34-treated mice that survived H-ARS were examined for residual bone marrow damage
(RBMD) up to 9mo post-exposure. Despite differences in Sca-1 expression and cell cycle position
in some hematopoietic progenitor phenotypes, Maxy-G34-treated mice exhibited the same degree
of hematopoietic stem cell (HSC) insufficiency as vehicle treated H-ARS survivors in competitive
transplantation assays of 150 purified Sca-1+cKit+lin-CD150+ cells. These data suggest that
Maxy-G34, at the dose, schedule, and time frame examined, did not mitigate RBMD, but
significantly increased survival from H-ARS at one-tenth the dose previously tested, providing
strong support for advanced development of Maxy-G34, as well as Neulasta, as MCM against
radiation.
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INTRODUCTION
In response to the growing threat of unintended radiation exposure from weapon or energy
sources, efforts have been underway worldwide to develop and ultimately license medical
countermeasures (MCM) against radiation for eventual stockpiling in case of a catastrophic
nuclear event. While low dose exposure of 1–2 Gy or less is generally non-life threatening,
exposures in the range of 2–10 Gy affect primarily the hematopoietic system, resulting in the
Hematopoietic Syndrome of the Acute Radiation Syndrome (H-ARS). H-ARS is
characterized by life-threatening neutropenia and thrombocytopenia, and possible death due
to infection and or bleeding. As there are currently no drugs approved to treat severely
irradiated personnel, physicians would likely rely on medications used to treat chemo- and
radiotherapy-induced myelosuppression, such as hematopoietic growth factors (HGF),
antibiotics, and fluids.
Likely HGF to be used after a radiation event include the granulopoietic cytokines
granulocyte-colony stimulating factor (G-CSF, Neupogen) and PEGylated-G-CSF
(Neulasta). Both molecules stimulate production of disease-fighting neutrophils, which help
prevent mortality from opportunistic infections after irradiation. G-CSF has been shown to
increase survival of lethally-irradiated animals when administered shortly after exposure
(Schuening et al. 1989, Schuening et al. 1993, MacVittie et al. 2005), but must be
administered in repeat daily doses for maximum efficacy. A single 1 or 2 mg kg−1 dose of
G-CSF 24h after 7–9.5 Gy exposure of mice was not able to improve survival (Neta and
Oppenheim 1988, Neta et al. 1988, Uckun et al. 1990). The requirement for repeat dosing
limits G-CSF’s attractiveness in a radiation accident scenario where casualties will be
numerous and medical facilities inundated.
Modification of G-CSF with polyethylene glycol (PEG) produces the molecule PEG-G-CSF,
or Neulasta, which possesses a reduced renal clearance and prolonged circulating half-life
compared to Neupogen (Abuchowski et al. 1984, Knauf et al. 1988, Molineux et al. 1999,
Bailon et al. 2001). PEGylated growth factors, such as Neulasta, have a treatment advantage
over non-PEGylated molecules due to their abbreviated dosing schedule, which would be
especially advantageous after a nuclear event. Neulasta has demonstrated efficacy in the
treatment of drug- and radiation-induced neutropenia in animals (Farese et al. 2012, Farese
et al. 2013) and humans (Gabrilove et al. 1988, MacVittie et al. 1990, Crawford et al. 1991,
Demetri 1992, Patchen et al. 1992, Bishop et al. 2000), following just one or two
administrations.
Maxy-G34 (Maxygen, Inc) is a novel PEGylated G-CSF designed to possess enhanced
efficacy compared to Neulasta via unique amino acid substitutions and additional PEG
moieties, resulting in reduced receptor binding and increased circulation time. Reduced
receptor binding results in reduced neutrophil-mediated elimination of Maxy-G34 compared
to G-CSFs with greater receptor affinity, resulting in increased half-life. In normal
volunteers, compared to Neulasta, Maxy-G34 was found to possess a 1.32.3-fold increased
half-life, 3.7-fold increase in bioavailability, and a 1.6-fold increase in the neutrophil
response using 50–70% less dose than Neulasta. In a clinical trial of breast cancer patients
with chemotherapy-induced neutropenia, Maxy-G34 showed a 2-fold increased half-life,
higher CD34+ cell counts post-nadir, and a lower incidence of febrile neutropenia compared
to Neulasta over a range of doses, some as low as 10% of Neulasta’s labeled dose
(Schwartzberg et al. 2009). Half-life and neutrophil response were also superior in rat
(Scholz et al. 2009) and non-human primate models (Farese et al. 2008) compared to
Neulasta. The increased potency, efficacy, and fewer required doses make Maxy-G34 an
attractive candidate MCM for use in the aftermath of a radiation event.
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Exposure to radiation and or chemotherapy is known to result in a latent condition termed
Residual Bone Marrow Damage (RBMD), whereby radiation-damaged hematopoietic stem
cells (HSC) are unable to provide normal hematopoiesis under times of stress. RBMD is
believed to be due to decreased self-renewal potential of HSC and induction of HSC
senescence (Hellman and Botnick 1977, Botnick et al. 1979, Mauch et al. 1988, Meng et al.
2003, Wang et al. 2006). Many RBMD studies show restoration of peripheral blood cell
counts, but a deficit of HSC and HPC function. The authors have recently examined RBMD
in mice surviving H-ARS and have documented severely deficient HSC potential in
competitive transplantation assays for up to 16 months post-exposure with severe skewing
toward the myeloid lineage (Chua et al. 2012). All classes of peripheral blood cells as well
as BM cellularity were significantly decreased, especially as H-ARS survivors aged. Given
the current environment and threat of terrorist use of radiation, the long term effects and
consequences of RBMD in survivors of H-ARS are of increasing concern. As survivors age,
the incidence of malignancy and other delayed effects of acute radiation exposure (DEARE)
increase, leaving H-ARS survivors particularly vulnerable to treatments resulting in
hematopoietic stress, such as chemo- or radio-therapy, in addition to aging itself. Thus,
mitigation strategies for not only H-ARS, but also for RBMD, are urgently needed.
Efficacy studies for screening candidate MCM, including Maxy-G34, require the use of
relevant, applicable, and practical animal models adhering to the Food and Drug
Administration’s (FDA) Animal Rule. Efforts in the authors’ laboratory to develop a murine
model in C57BL/6 mice of H-ARS have recently been published (Plett et al. 2012). This
model has been extensively validated through its use to screen multiple candidate
radiomitigators, and can be used for Good Laboratory Practices (GLP) experiments, as
recommended by the FDA’s Animal Rule. The current study uses this murine model to
assess the ability of Maxy-G34 to mitigate the acute effects of H-ARS in comparison to a
known radiomitigator, Neulasta. In addition, mice surviving H-ARS after treatment with
Maxy-G34 were assessed at various times up to 9mo post-exposure to determine whether
treatment with Maxy-G34 for H-ARS in youth has any beneficial effect to mitigate the
deleterious effects of RBMD in aged survivors of H-ARS.
MATERIALS AND METHODS
Mice
For H-ARS studies, specific pathogen free C57BL/6 mice (50/50 male/female; Jackson
Laboratory, Bar Harbor, Maine) were received at 10 weeks of age, an age analogous to a
“young adult” human. Weights of mice in the survival studies ranged from 15.0–22.5 g
(females) and 20.0–28.0 g (males). Mice were identified by tattoo or ear punch, and or tail
marks. Husbandry and health status monitoring were carried out as previously described
(Plett et al. 2012). Briefly, mice were housed in microisolator cages and provided with
autoclaved acidified water in sipper tubes and wet feed between d4–30 post-irradiation.
Irradiated mice were observed twice daily and scored a scale of zero to three for signs
meeting the criteria for early euthanasia based on the severity of hunched posture, squinted/
closed eyes, and activity (Plett et al. 2012). Mice with scores of eight or nine underwent
euthanasia by CO2 inhalation followed by cervical dislocation (Plett et al. 2012). Overall,
11–67% of dead mice in these studies underwent humane euthanasia, as opposed to being
found dead by animal caretakers.
For RBMD studies, mice were fed with regular chow and acidified water. Recipient mice
and donors of competitor cells used in competitive transplantation assays were of the
congenic PtrcaPep3b/BoyJ (B6.BoyJ; CD45.1+) or the F1 hybrid of C57Bl/6 and B6.BoyJ
mice (CD45.2+CD45.1+) strains. These two strains were used interchangeably as transplant
recipients and competitor cell donors, and their leukocytes were distinguished from C57Bl/6
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cells in transplant recipients by expression of CD45.1. B6.BoyJ and F1 hybrid mice were
bred in-house and used between 8–12 wk of age. All studies were approved by the Indiana
University School of Medicine Institutional Animal Care and Use Committee.
Irradiation and dosimetry
Irradiation and dosimetry were performed as previously described (Plett et al. 2012). Mice
for H-ARS studies were exposed in single chambers of a Plexiglas irradiation apparatus to
single uniform total body irradiation (TBI) doses ranging from 7.76 to 9.04 Gy gamma
radiation from a 137Cs radiation source at (GammaCell 40; Nordion International, Kanata,
Ontario, Canada; 0.60–0.66Gy min−1). Annual calibration of the radiation dose-lethality
relationship in the authors’ laboratory resulted in slightly different LDXX/30 doses over the
time period that the studies were conducted, as shown in Table 1.
Complete blood counts (CBC)
Mice were tail-bled and blood was analyzed for complete blood count (CBC) values using a
validated HEMAVET® 950FS Hematology System (Drew Scientific, Waterbury, CT) at
least 10min after collection but within 24h.
Maxy-G34 manufacture
Maxy-G34 was engineered to contain 5 amino acid substitutions of the native human G-CSF
protein and 3 polyethylene glycol (PEG) conjugations at unique sites. Maxy-G34 was
selected by screening approximately 100 candidates to minimize G-CSF receptor-mediated
clearance and renal excretion. The novel protein sequence and PEGylation pattern of Maxy-
G34 resulted in reduced binding affinity for the G-CSF receptor and receptor-mediated
internalization (unpublished data).
Neupogen, Neulasta and Maxy-G34 administration
The radiomitigators were administered subcutaneously post-TBI as described below.
Control groups were similarly injected but with vehicle specified below.
Neupogen—One administration schedule was tested, 125 ug kg−1, one dose administered
at 24±4 h post-TBI, then daily from d2 to d16 for a total of 16 doses. Vehicle: 0.9% saline
(w/v) + 0.1% bovine serum albumin (BSA) solution, or 5% (D)-Glucose solution.
Neulasta—Two different administration schedules were tested, 1) 0.1 mg kg−1, 0.3 mg
kg−1, or 1.0 mg kg−1, one dose of each concentration administered to separate groups at
24±4h post-TBI, or 2) 1.0 mg kg−1, two doses administered at 24±4h and d7 post-TBI.
Vehicle: 0.9% saline (w/v) + 0.1% BSA solution. The 1 mg kg−1 dose of Neulasta used in
this study was chosen based on doses used in chemotherapy myelosuppression models
(Molineux et al. 1999, Lord et al. 2001).
Maxy-G34—Three different administration schedules were tested, 1) 0.1 mg kg−1, 0.3 mg
kg−1, or 1.0 mg kg−1, one dose of each concentration administered to separate groups at
24±4h post-TBI, or 2) 1.0 mg kg−1, two doses administered at 24±4h and d7–8 post-TBI, or
3) 1.0 mg kg−1, three doses administered at 24±4h and d7–8 and d14–15 post-TBI. Vehicle:
Sodium acetate (10 mM), mannitol (45 mg mL−1), polysorbate 20 (0.05 mg mL−1), pH 4.0,
solution. The doses of Maxy-G34 used in this study were chosen to be the same as doses of
Neulasta.
For RBMD studies: two different Maxy-G34 administration schedules were used, 1) 1.0 mg
kg−1, one dose at 24±4h post-TBI, or 2) 1.0 mg kg−1, two doses at 24±4h and d8 post-TBI.
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Vehicle: Sodium acetate (10 mM), mannitol (45 mg mL−1), polysorbate 20 (0.05 mg mL−1),
pH 4.0, solution.
Residual bone marrow damage studies
Mice treated with one or two doses of 1.0 mg kg−1 Maxy-G34 or vehicle in experiment
11.215, 8.29 Gy (Table 1), and which survived H-ARS, were assessed at 4 and 6 months (2
doses of Maxy-G34), and 7 and 9 months post-TBI (1 dose of Maxy-G34), along with non-
TBI age-matched controls. Survival of mice at 30 days post-TBI (Table 1) was the same as
that at 4 months post-TBI, the first time point analyzed in the RBMD studies. At each time
point, mice were assessed for body weight, CBC, bone marrow (BM) cellularity, BM
hematopoietic progenitor number, lymphoid progenitor number, primitive hematopoietic
progenitor phenotypes, cell cycle analyses, and HSC multilineage reconstitution potential in
competitive transplantation assays, all as previously described (Chua et al. 2012). Flow
cytometry analyses of primitive hematopoietic progenitor populations analyzed Sca-1-bright
cells, in addition to total Sca-1+ cells analyzed in previous studies Chua et al. 2012). Sca-1-
bright cells represent a more primitive hematopoietic population than total Sca-1 cells. Data
generated from either analysis did not differ in trend, so only Sca-1-bright analyses are
presented in Results.
Study design, sample size, & statistical analyses
Survival studies—Each cage was randomized to a radiation exposure dose and individual
mice were randomized to treatment groups by a study statistician. Studies testing MCM as
mitigators were powered to detect a 30% reduction in mortality (i.e. 70% to 40%, 90% to
60%) with 80% power using a two-tailed 5% significance level. The primary outcome, 30-
day survival, was examined using logistic regression, which also included sex, radiation
dose and interactions of treatment with dose and gender to examine differential effects.
Since the randomization was by mouse, “cage effects”, if present, did not bias the results but
the model was adjusted using a Generalized Estimating Equations (GEE) method. Cage
effects (differences between cages on the same treatment) can occur as a result of infection,
or differences in environment due to cage position. Secondary analysis included time to
death (overall survival), and was examined using a Cox proportional hazards regression
model, which was analogous to the logistic regression and included treatment, gender and
radiation dose. Mean survival Time (MST) of decedent mice was performed using analysis
of variance including radiation dose as a factor.
Individual survival studies were conducted using 1–3 radiation doses and results from each
were analyzed within each study for survival. For ease of presentation, results are presented
within study in Table 1, but combined across radiation doses in the figures. Studies were
powered to test for the main effect across all irradiation dose groups in the statistical model
adjusted for dose. The statistical analysis included tests for interactions between the
radiation dose and treatment for survival. If a significant interaction (indicating a differential
treatment effect for the two doses) was detected, the dose groups were analyzed separately.
The interactions between radiation dose and treatment for survival were not observed in any
these studies and therefore the results for overall tests are presented.
RBMD studies—The Student’s unpaired t-test was used to compare the following
parameters among TBI-cont, TBI-G34 and non-TBI: weight, CBC parameters, BM
cellularity, percent and number per mouse of BM primitive hematopoietic cells, progenitor
content per mouse, donor chimerism and %G0G1 of lin-, KSL and KSLCD150+ cells.
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RESULTS
Survival of irradiated mice after administration of G-CSF, Neulasta, or Maxy-G34
The authors have previously published significantly increased survival of lethally-irradiated
mice treated with 16 daily doses of 125 ug kg−1 Neupogen in their murine model of H-ARS
(Plett et al. 2012). They now show pooled data from 9 similar studies where a total of 212
lethally-irradiated mice were injected with 16 daily doses of 125 ug kg−1 Neupogen and
monitored for 30d survival. Neupogen treated mice showed significantly increased 30d
survival (80.2%) compared to vehicle-treated mice (51.6%, p=0.02, Fig. 1a), further
validating the use of this murine model of H-ARS to test candidate MCM and the strong
survival efficacy of Neupogen in H-ARS.
The use of PEGylated HGF has favorable logistical advantages in the aftermath of a nuclear
event since fewer injections are required for efficacy. To investigate efficacy of PEGylated
granulopoietic HGF in our murine H-ARS model, groups of 20–30 C57BL/6 mice were
exposed to lethal TBI with gamma radiation as previously described (Plett et al. 2012) and
treated with either Maxy-G34 or Neulasta. One dose of 1.0 mg kg−1 (24 ± 4hr post-TBI) of
Neulasta was found to be equally effective at increasing 30d survival as two doses of the
same concentration, given at 24 ± 4hr and on d7 post-TBI (p=0.003 and p=0.004,
respectively, Figure 1b), suggesting the possibility that one administration might be
sufficient for enhancing survival after a radiation event.
Likewise, different administration schedules of 1.0 mg kg−1 Maxy-G34 were examined for
survival efficacy: one dose at 24 ± 4hr post-TBI, two doses at 24 ± 4hr and d7 or 8 post-
TBI, and three doses at 24 ± 4hr, d7 or 8, and d14 or 15 post-TBI. Each administration
schedule was examined in three to five separate studies for a total of eleven studies. Similar
to Neulasta, each administration schedule of Maxy-G34 significantly increased 30d survival
of treated mice compared to vehicle treated mice (Figure 1c), suggesting that this novel
PEG-G-CSF may also provide sufficient survival efficacy in a one dose administration
schedule.
Evident in these results was the variability in control group survival. The high survival in the
control groups was an unintended consequence of the steep radiation dose response curve
observed in inbred strains of mice (such as C57Bl/6 used in these studies) and discussed in
the authors’ previous publication (Plett et al. 2012). The very steep curves mean that
confidence intervals around the calculated LDXX/30 radiation doses span a larger fraction
of the curve, thus pinpointing the LDXX/30 in subsequent experiments becomes difficult.
Table 1 shows the intended and actual LDXX/30 in all experiments in Figures 1 and 2.
Mean survival time (MST) of decedent mice was significantly decreased in Neupogen-
treated mice, compared to vehicle controls (14.3 and 17.6 days, respectively, p<0.001, Table
2). The shortened MST in the Neupogen-treated mice reflects the finding that onset of death
in each group occurs at approximately the same time (day 9 in this study), but deaths in
vehicle-treated mice continued to day 29, while the last death in the Neupogen group was on
day 17. Since MST is calculated only from decedent mice, MST of groups where mice
continue to die until late time points will be increased.
While the MST in the Neulasta group was slightly decreased compared to controls, data
could not be analyzed statistically due to the fact that only 1 mouse died in each of the
Neulasta groups (Table 2).
Similar to Neupogen, a significantly decreased MST was observed in the Maxy-G-34-
treated mice compared to vehicle controls (13.3 and 19.9 days, respectively, combining all
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Maxy-G34-treated and all vehicle-treated mice, p=0.001, Table 2). In these studies, as with
Neupogen, lethality in each group commenced on the same day (day 8), but ended earlier in
the Maxy-G34-treated mice (day 17) than in controls (day 28).
Dose reduction of Maxy-G34 and Neulasta with retention of survival efficacy
To investigate whether doses lower than 1.0 mg kg−1 of the PEGylated-G-CSF molecules
Maxy-G34 and Neulasta retain survival efficacy in lethally irradiated animals and therefore
might be safer if administered to presumably healthy individuals in the aftermath of a
nuclear event, 1.0, 0.3, and 0.1 mg kg−1 of each MCM were evaluated in the murine H-ARS
model for survival efficacy. Remarkably, the lowest dose assayed of both Maxy-G34 and
Neulasta provided 30d survival efficacy that was similar to a 10-fold higher dose of 1.0 mg
kg−1, and the 3-fold higher dose of 0.3 mg kg−1 (Figure 2, p<0.001 for all groups versus
control). MST, unlike that in the previous Maxy-G34 studies discussed in Fig 1, were not
statistically different between Maxy-G-34- or Neulasta-treated mice compared to vehicle
controls (Table 3).
These data suggest that doses lower than those currently proposed for use in lethally-
irradiated personnel may provide sufficient survival efficacy, thereby reducing the potential
for harmful side effects in people not at risk for neutropenia, as well as treatment costs.
Residual bone marrow damage in survivors of H-ARS treated with Maxy-G34
Exposure to radiation and or chemotherapy is known to result in a latent condition termed
Residual Bone Marrow Damage (RBMD), whereby radiation-damaged HSC are unable to
provide normal hematopoiesis under times of stress. The authors have examined RBMD for
up to 2 years post-TBI in mice surviving H-ARS and have documented severe deficiencies
in all classes of hematopoietic cells, especially as mice aged (Chua et al. 2012). Given the
current environment and threat of terrorist use of radiation, the long term effects and
consequences of RBMD in survivors of H-ARS are of increasing concern. In this regard, it
is important to investigate whether mitigators that successfully increase survival from H-
ARS, also mitigate some of the deleterious effects of RBMD in aged survivors.
To this end, mice from experiment 11.215, 8.29 Gy in Table 1 that were lethally irradiated,
treated with one dose (on d1) or two doses (on d1 and 8 post-TBI) of 1.0 mg kg−1 Maxy-
G34, and survived H-ARS, were assessed for RBMD as previously described (Chua et al.
2012). Such mice are referred to hereafter as “TBI-G34”. Survivors among vehicle treated
control mice (referred to as “TBI-cont”), as well as non-irradiated age-matched controls
(referred to as “non-TBI” mice) were also assessed for RBMD. Mice treated with two doses
of Maxy-G34 were assessed at 4 and 6mo post-TBI, while mice treated with one dose of
Maxy-G34 were assessed at 7 and 9mo post-TBI.
Body weights
Body weights of both groups of TBI mice at 4, 6, 7, and 9 mo post-TBI, as a whole, were
significantly less than non-TBI mice (p<0.01, data not shown), similar to the authors’
previously reported findings for TBI-cont mice (Chua et al. 2012). Fur color of both groups
of TBI mice was also lighter than that of non-TBI mice, as previously reported (Chua et al.
2012).
CBC
Of interest, neutrophil counts in TBI-G34 mice were significantly higher than those in TBI-
cont mice at 4mo post-exposure (Fig. 3b line graph and inset bar graph). Similarly,
percentage of neutrophils was significantly higher in TBI-G34 mice at 4mo compared to
non-TBI mice (31.1 ± 4.2% versus 16.3 ± 2.9%, respectively, p=0.029). These data illustrate
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the persistence of the enhancing effect of Maxy-G34 on neutrophil recovery to as long as
4mo post-exposure. Neutrophil counts in all three groups of mice were similar at time points
beyond 4mo (months 6, 7, and 9 post-TBI, Fig. 3b), although overall percentages of
neutrophils were significantly increased in both TBI-cont and TBI-G34 compared to non-
TBI mice (overall means ± SEMs: 34.4 ± 4.4%, 32.2 ± 2.8%, and 24.0 ± 1.8%, respectively,
p=0.011 for each comparison), similar to previously reported findings for TBI-cont mice
(Chua et al. 2012).
The percentage of lymphocytes was significantly less in TBI-cont and TBI-G34 mice over
time as compared to non-TBI mice (overall means ± SEMs: 61.5 ± 4.5%, 63.8 ± 2.6%, and
71.7 ± 1.7%, respectively, p=0.011 for each comparison), illustrating the significant impact
that radiation exposure poses on the immune system.
Differences in CBC parameters other than neutrophils at 4mo among the two TBI groups
and non-TBI mice were not consistent or apparent (Fig. 3). These data are not surprising
given the authors’ previous findings that CBC parameters of TBI mice appeared similar to
those of non-TBI mice up to approximately 9–10mo post-exposure, but tended to decrease at
time points beyond 10mo as the mice aged (Chua et al. 2012).
BM cellularity and primitive hematopoietic phenotypes
Overall BM cellularity in both groups of TBI mice was significantly less than that in non-
TBI mice by 30–70% of non-TBI values (p<0.05), with no apparent effects of Maxy-G34
treatment (Fig. 4a). Similar to the authors’ previous report (Chua et al. 2012), the percentage
of lineage-negative (lin-) cells was generally higher in both TBI groups compared to non-
TBI mice, but because BM cellularity was lower in TBI mice, absolute numbers of lin- cells
were similar between all three groups (data not shown).
The authors’ previous data demonstrated significantly decreased percentage and number of
primitive BM KSL cells in TBI mice compared to non-TBI (Chua et al. 2012), consistent
with data reported herein (Fig. 4d and 4e). Of interest in the current study is that
administration of Maxy-G34 as a radiomitigator for H-ARS appears to have effected a
further decrease in the percentage and absolute numbers of primitive BM HPC populations.
The overall percentage of Sca-1-bright+ cells, Sca-1-bright+ cKit+ cells, Sca-1-bright+ cKit
+ lin-, and absolute numbers of Sca-1-bright+ cKit+ lin-, were all significantly decreased in
TBI-G34 mice compared to TBI-cont and or non-TBI mice (Fig. 4b, 4c, 4d, and 4e,
respectively). Expression of cKit on lin- cells did not differ in any of the three groups (data
not shown).
Similar to the authors’ and others’ data (Simonnet et al. 2009), expression of CD150 on KSL
cells from both groups of TBI mice was significantly increased compared to non-TBI mice
(Fig. 4g, p=0.001), while absolute numbers of KSLCD150+ cells were similar (due to lower
numbers of KSL in TBI mice, Fig. 4h).
BM hematopoietic progenitor cells (HPC) and pre-B lymphoid colonies
Absolute numbers of the BM hematopoietic progenitors CFU-GM, BFU-E, CFU-GEMM,
and pre-B cell progenitors were all found to be significantly decreased in both groups of TBI
mice compared to non-TBI mice (Figs. 5a–d), similar to the authors previous findings (Chua
et al. 2012). There were no significant differences in progenitors from TBI-G34 versus TBI-
cont mice.
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Competitive transplantation and lineage reconstitution
The long term engraftment potential of 150 purified, sorted KSLCD150+ donor cells derived
from Maxy-G34 or vehicle treated TBI mice was determined at 4, 6, 7, or 9 mo post-TBI in
a competitive repopulation assay along with similar cells from non-TBI mice. Fig. 6 shows
donor-derived chimerism at 6 mo post-transplant for a total of 38 recipients of TBI-cont
cells, 30 recipients of TBI-G34 cells, and 36 recipients of non-TBI cells. Evident from the
figure is that chimerism for both groups of TBI mice was severely depressed compared to
non-TBI mice at every time point analyzed post-TBI, similar to the authors’ previous
findings with TBI-cont KSLCD150+ cells (Chua et al. 2012).
Recipients with at least 0.05% donor chimerism at 6mo post-transplant were further
analyzed for multilineage reconstitution of peripheral blood CD8+ T cells, CD4+ T cells,
B220+ B cells, and Gr-1+ granulocytes by flow cytometry. As previously described for TBI-
cont mice (Chua et al. 2012), recipients of KSLCD150+ cells isolated from both groups of
TBI mice were deficient in B-cell reconstitution with skewing toward the myeloid lineage at
every time point analyzed (Fig. 7a and 7b) compared to recipients of similar cells from non-
TBI mice (Fig. 7c), or competitor cells co-transplanted with any of the test groups of cells
(Fig. 7d, 7e, and 7f). Reconstitution of CD8+ T-cells did not differ among groups, while
reconstitution of CD4+ cells was significantly less in TBI-G34 mice compared to non-TBI
(Fig. 7b and 7c).
Cell cycle analysis
One of the hallmarks of HSC is their high degree of mitotic quiescence, which is believed to
be essential for life long hematopoiesis, self-renewal, differentiation, and efficient homing to
their BM microenvironment following transplantation (Verfaillie and Miller 1995, Peters et
al. 1996, Traycoff et al. 1996, Ladd et al. 1997, Nilsson et al. 1997, Gothot et al. 1998,
Habibian et al. 1998). Data in Figs. 6 and 7 show deficient long term repopulating ability of
candidate HSC isolated from aged mice that survived the lethal effects of H-ARS after
treatment with Maxy-G34, as well as few mice that survived without treatment. Data in Fig.
8a–c show significantly increased cell cycling of primitive lin-, KSL and KSLCD150+ from
TBI-cont mice compared to similar cells from non-TBI mice, consistent with the authors’
previous findings (Chua et al. 2012). Despite a few time points where the %G0/G1 of these
phenotypes from TBI-G34 mice were similar to those from non-TBI mice, in general there
was no consistent effect of Maxy-G34 administration months prior on cell cycling during the
observed 4–9 months post-TBI time frame.
DISCUSSION
This paper investigates survival efficacy, effective dose levels, and administration schedules
of three granulopoietic growth factors of potential value in a radiation/nuclear event for
treatment of personnel suffering from H-ARS. G-CSF (Neupogen) and the PEG-G-CSF
molecules Neulasta and Maxy-G34, all significantly increased 30d survival from lethal
radiation in a mouse model of H-ARS. Of these, G-CSF is currently stockpiled for use in
case of a radiation event. G-CSF has proven survival efficacy in several animal models of
H-ARS including canine (Schuening et al. 1989, Schuening et al. 1993, MacVittie et al.
2005), mini-pig (Moroni et al. 2013), non-human primate (Farese et al. 1996, Drouet et al.
2008, Farese et al. 2013), in addition to mouse (Patchen et al. 1990, Patchen et al. 1992,
Patchen et al. 1993, Patchen and MacVittie 1994, Patchen 1995), and is the lead candidate
MCM for licensure under the FDA’s Animal Rule. The authors have shown that survival
efficacy of G-CSF in murine H-ARS is strongly linked to the secondary parameter of
neutrophil recovery (Plett et al. 2012), providing a plausible mechanism of action for this
MCM.
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The relatively short half-life of G-CSF requires that it be administered as repeat daily
injections for maximum survival efficacy (Neta and Oppenheim 1988, Neta et al. 1988,
Uckun et al. 1990). To circumvent this apparent disadvantage for a mass causality event,
efforts have been underway in the authors’ and others laboratories (Dainiak et al. 2003,
Herodin et al. 2007, Drouet et al. 2008) to investigate survival efficacy of longer acting
granulopoietic growth factors. The authors have shown enhanced neutrophil recovery in a
radiation-induced myelosuppression model in rhesus macaques using the PEGylated form of
G-CSF, Neulasta (Farese et al. 2012). In the current study, Neulasta was shown to provide
enhanced survival in a lethal radiation model of H-ARS in mice. Of particular importance,
one dose of Neulasta given 24h post-exposure was shown to be as efficacious as 2 doses
given on days 1 and 7, a dosing schedule with obvious advantages in the aftermath of a
radiation event.
In efforts to expand the pool of MCM worldwide to avoid shortage in the event of
widespread need, other pegylated G-CSF are being evaluated for survival efficacy in H-
ARS. Of these, Maxy-G34 (Maxygen, Inc) is a unique PEG-G-CSF that has been
specifically designed to provide prolonged activity. Maxy-G34 has been shown in both
normal volunteers and cancer patients to possess a longer half-life and more potent
hematopoietic effects than Neulasta, at lower doses that those recommended for Neulasta
(Schwartzberg et al. 2009). Similar results have been found in animal models (Farese et al.
2008, Scholz et al. 2009). In the current study, 1 dose of Maxy-G34 was found to be as
effective as 2 or 3 doses to significantly increase 30d survival in a mouse model of H-ARS,
similar to Neulasta. Given its favorable dosing schedule, improved leukocyte response
(Schwartzberg et al. 2009), and longer half-life compared to Neulasta, Maxy-G34 is an
extremely attractive candidate for licensure and stockpiling in preparation for a possible
radiation event.
Optimal use of PEGylated HGF in the aftermath of a nuclear event would be targeted to
those whose level of exposure places them at risk for life-threatening neutropenia and in
need of HGF treatment. At least two challenges exist to such optimal delivery of treatment.
First, safe treatment with such potent MCM relies on timely and accurate biodosimetry to
identify those victims who face the greatest risk. Current biodosimetric methods are time-
consuming and imprecise, and may not provide accurate biological dose-estimations within
a logistically- or medically-feasible time frame. Second, the so-called “worried-well” may
want medical treatment that may not be warranted or in their best interest. Treatment of
healthy individuals with PEGylated HGF exposes them to the known side effects of the drug
and is difficult to “undo” due to the long half-life imparted by the PEG moiety. A potential
solution to this dilemma would be to administer lower doses of PEGylated MCM that retain
survival efficacy in lethally-irradiated personnel, but would be less dangerous if given to
healthy, non-irradiated people, since side effects would be presumably less severe and
subside more rapidly. The data presented herein show equal survival efficacy of Maxy-G34
and Neulasta at one-tenth the dose previously tested in murine models of H-ARS. These data
suggest that lower doses of PEG-G-CSF than those previously thought to be required for
survival efficacy may be used, which would likely limit the harmful effects if administered
to non-irradiated personnel.
The dose of Neulasta used in this study was selected based on previous studies modeling
bone marrow myelosuppression in mice treated with 150 mg kg−1 5-FU (Molineux et al.
1999), or 200 mg kg−1 cyclophosphamide plus 90 mg kg−1 temozolomide (Lord et al. 2001).
Molineux et. al. (Molineux et al. 1999) showed that 1 mg kg−1 Neulasta was more effective
than 0.5 mg kg−1 Neulasta or 5 daily doses of 300 ug kg−1 Neupogen at reducing both the
depth and duration of neutropenia in the myelosuppressed mice. Lord et. al. showed that 1
mg kg−1 Neulasta was as effective as 4 daily doses of 125 ug kg−1 Neupogen at inducing
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granulopoiesis (Lord et al. 2001). Doses of Neulasta used in the Molineux study (Molineux
et al. 1999) were chosen by the authors to provide the equivalent amount of G-CSF protein
only; the molecular weight of the PEG moiety was factored into the calculations.
Radiation-induced neutropenia results in loss of the “neutrophil sink” as a clearance
mechanism of G-CSF, which may contribute to the observed enhanced efficacy of lower
doses of these two PEG-G-CSF molecules through increased PK in irradiated mice. At
lower radiation doses than those used herein, or where a portion of the mouse is shielded
during exposure, some neutrophils may remain or at least be regenerated more quickly.
These neutrophils will absorb the PEG-G-CSF molecules, remove them from circulation,
resulting in shortened half-life compared to the longer half-life observed during absolute
neutropenia. In the current study, such a situation may have a larger impact on the half-life
of Neulasta than Maxy-G34, since Maxy-G34 is designed to have low receptor affinity, thus
its half-life would not be influenced by circulating neutrophils to the same degree as the
half-life of Neulasta. It is tempting to speculate that in such a scenario, efficacy of low doses
of Maxy-G34 may be greater than low doses of Neulasta, since half-life of Maxy-G34 would
be longer. Future studies are warranted to investigate this possibility as current modeling
studies predict that a considerable percentage of the population would experience partial
marrow shielding during a radiation event, allowing survival of neutrophils that would
contribute to clearance of G-CSF MCM.
G-CSF treatment has been associated with secondary malignancy in diseases such as ALL
(Relling et al. 2003), breast cancer (Smith et al. 2003), and severe congenital neutropenia
(Rosenberg et al. 2006, Germeshausen et al. 2007, Touw and Bontenbal 2007), raising
concern that use of granulopoietic cytokines in irradiated personnel may also result in
increased incidence of secondary malignancy later in life. An additional attractive feature of
using lower doses of PEG-G-CSF MCM during a mass casualty event is that lower doses
may reduce the possibility of treatment-associated secondary malignancy. To date, the
incidence of malignancy in the current studies does not appear to be increased in mice
treated with Maxy-G34 compared to vehicle treated mice (data not shown), but long term
monitoring of H-ARS survivors and larger group sizes are necessary to adequately
investigate risk of malignancy. Such studies were beyond the scope of this investigation.
Additional studies are required to examine whether a further dose reduction is possible,
while maintaining survival efficacy.
The authors have previously described residual bone marrow damage (RBMD) in murine
survivors of H-ARS up to 20mo post-TBI [(Chua et al. 2012) and unpublished
observations]. In those studies, CBC of TBI survivors were comparable to those of non-TBI
age-matched controls up to approximately 10mo of age, but became significantly decreased
at later time points. HSC and HPC were significantly decreased in TBI mice at every time
point analyzed up to 20mo post-TBI [(Chua et al. 2012) and unpublished observations].
Clearly, survival from H-ARS will be met with a myriad of chronic afflictions later in life,
including RBMD, and mitigation strategies against the delayed effects of acute radiation
exposure (DEARE) must be actively pursued. To this end, the authors compared RBMD in
mice surviving H-ARS after treatment with 1.0 mg kg−1 Maxy-G34 (TBI-G34), vehicle
(TBI-cont), and non-TBI controls to examine whether Maxy-G34 treatment for H-ARS also
mitigated of the some of the deleterious effects of RBMD.
Treatment with Maxy-G34 for H-ARS resulted in significantly increased neutrophils at 4mo
post-TBI. The authors have previously shown that significantly increased survival from H-
ARS is linked to enhanced recovery of neutrophils in G-CSF-treated mice (Plett et al. 2012).
The current data suggest that significant increases in neutrophil levels of mice treated with
granulopoietic cytokines may persist to 4mo post-TBI, or alternatively, that the longer half-
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life of Maxy-G34 exerts neutrophilic effects beyond the 30d time frame of H-ARS that may
not be seen with shorter-acting G-CSF. Studies comparing neutrophil recovery beyond 30d
in H-ARS after treatment with either G-CSF or Maxy-G34 are needed to investigate any
potential differences between the two MCM in long-term neutrophil reconstitution.
Of particular interest in the current study is the overall significant decrease in lineage-
negative BM cells expressing Sca-1 in mice treated with Maxy-G34. The consequence, if
any, of the observed decrease in Sca-1 expression for hematopoiesis and or RBMD in Maxy-
G34-treated mice is unknown. In fact, the function of Sca-1 in hematopoiesis is largely
unknown, and the existence of a ligand for the Sca-1 receptor remains an enigma. Sca-1 is
expressed on all classes of murine HSC and HPC, and mechanisms for its up- and down-
regulation are unclear (Kondo et al. 1997, Akashi et al. 2000). In mice and normal humans,
G-CSF administration has been shown to increase plasma levels of TNF-alpha and TGF-
beta, which in turn resulted in decreased Sca-1 expression on myoblasts and T cells (Long et
al., Xu et al. 1996, Hirayama et al. 2002). Decreased Sca-1 expression in these studies was,
however, reversible and only apparent during the time frame that G-CSF was present, and
thus cannot directly explain our findings of decreased Sca-1 expression 9 mo after a single
injection of Maxy-G34.
Other studies suggest a role for Sca-1 in HSC self-renewal and lineage determination (Ito et
al. 2003, Bradfute et al. 2005), two key characteristics of HSC. Data in the current paper
show no difference in either parameter between TBI-G34 and TBI-cont mice. Given the
authors’ previous findings that hematopoietic deficiencies in H-ARS survivors were most
pronounced beyond 10mo of age (Chua et al. 2012), it is possible that differences between
TBI-G34 and TBI-cont mice may be more apparent at later time points, when the stress of
RBMD is coupled with that of aging. Whether Sca-1 expression in other organ systems
(bone, muscle, kidney, brain, etc.) (Holmes and Stanford 2007) is similarly affected by prior
Maxy-G34 administration, is unknown, but of potential importance in the context of
DEARE.
The decreased expression of Sca-1 resulted in significantly decreased percentage and
absolute numbers of KSL cells in TBI-G34 mice compared to TBI-cont. However, due to
the radiation-induced increased expression of CD150 on KSL (Simonnet et al. 2009, Chua et
al. 2012), absolute numbers of KSLCD150+ cells were similar among all three groups,
consistent with the authors’ previous report (Chua et al. 2012).
Competitive multilineage repopulating potential, the only true test of HSC, of KSLCD150+
cells purified from both groups of TBI mice was significantly decreased at every time point
analyzed compared to similar cells from non-TBI mice. Both groups of TBI cells provided
predominantly myeloid reconstitution and deficient lymphoid reconstitution, similar to the
authors’ previous findings (Chua et al. 2012) for TBI-cont mice. These data illustrate the
severity of damage in HSC and the hematopoietic system in survivors of H-ARS, and
inability of Maxy-G34, albeit its successful mitigation of H-ARS, to enhance recovery from
RBMD.
It is possible, as previously suggested for Neupogen in myelosuppressive protocols (van Os
et al. 2000), that Maxy-G34 stimulated proliferation and differentiation of the few remaining
HSC following exposure to lethal radiation at the expense of self renewal, resulting in the
manifestations of RBMD. This is unlikely since the cell cycle status of some classes of HPC
in TBI-G34 mice were not significantly different overall from non-TBI mice, while such
cells from TBI-cont mice were more actively cycling. The less-damaged marrow and higher
number of HPC/HSC remaining after the myelosuppressive protocol used in the van Os
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study compared to the severe BM damage after TBI myeloablation, are key differences that
may impact the effects of granulopoietic cytokines on primitive HPC function.
The similar cell cycle status of TBI-G34 and non-TBI primitive HPC was most apparent at 4
and 6mo post-TBI in lin-cells. It is curious that changes in Sca-1 expression in TBI-G34
mice were also most apparent in the lin- population. The biological significance, if any, of
these findings is unknown. Given the strong association of mitotic quiescence with HSC
function, further investigation of these findings may be warranted since the possibility exists
that they may signify a potential mechanism to restore quiescence in HSC from H-ARS
survivors.
It is possible that HSC in H-ARS survivors are different phenotypically and/or reside in a
different location than those from steady state marrow, and were missed in the current
analyses. Given the ability of granulopoietic cytokines to mobilize HSC from the marrow,
coupled with a radiation-damaged HSC niche, the possibility of extramedullary
hematopoiesis in TBI-G34 mice is worth investigation. The low levels of chimerism (<10%)
from both groups of TBI mice may have meant that the assay was near the lower limit of
detection, and that detecting differences in the negligible HSC potential between the two
groups of H-ARS survivors would not have been possible. However, the significance of
determining small differences in HSC potential, when levels are so low regardless, is
questionable.
Transplantation of purified HSC phenotypes in this study, rather than unfractionated bone
marrow, allowed differentiation between radiation-induced deficits in quality versus
quantity of HSC. The authors’ finding of lower chimerism from both groups of TBI
KSLCD150+ cells indicates functional damage to HSC (i.e. reduced quality). Had
unfractionated cells been transplanted instead of purified HSC phenotypes, it would have not
been possible to distinguish between lower chimerism levels due to reduced numbers of
HSC (quantity) or reduced function (quality), but would have allowed detection of HSC in
the event that the phenotype had changed in H-ARS survivors.
CONCLUSIONS
Collectively, these data document significantly increased 30 day survival in a murine model
of H-ARS of three candidate radiomitigators, G-CSF (Neupogen), PEG-G-CSF (Neulasta),
and the novel PEG-G-CSF, Maxy-G34, which possesses increased half-life and enhanced
hematopoietic activity compared to Neulasta. Both PEG-G-CSFs were shown to retain
significant survival efficacy when administered as a single dose, and at one-tenth the dose
previously used in survival studies, favorable characteristics for use in a mass casualty
event. Mice surviving from H-ARS were examined for RBMD up to 9mo post-exposure.
Despite differences in Sca-1 expression and cell cycle position in some hematopoietic
phenotypes, TBI-G34 mice possessed the same degree of hematopoietic insufficiency as
vehicle treated TBI-cont mice in competitive transplantation assays. These data suggest that
Maxy-G34, at the dose, schedule, and time frame examined, did not mitigate RBMD, but
significantly increased survival from H- ARS at one-tenth the dose previously tested,
providing strong support for advanced development of Maxy-G34 as a MCM against
radiation.
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Fig. 1.
Survival of lethally-irradiated mice after Neupogen, Neulasta, or Maxy-G34 administration.
Fig 1a: mice were exposed to a single dose of radiation between 7.76–9.04 Gy and injected
subcutaneously with one dose of 125 ug kg−1 Neupogen (G-CSF) at 24 ± 4h, then daily to
d16 (filled bars). Control mice were similarly injected but with vehicle (open bars). Figure
1a includes data previously published by the authors (Plett et al. 2012). Fig 1b: mice were
exposed to a single dose of radiation (7.76 or 7.96 Gy) and injected subcutaneously with one
dose of 1.0 mg kg−1 Neulasta (PEG-G-CSF) at 24 ± 4h, or two doses at 24 ± 4h and d7 post
irradiation (filled bars); control mice were similarly injected but with vehicle (open bars).
Fig 1c: mice were exposed to a single dose of radiation between 7.76–8.29 Gy and injected
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subcutaneously with one dose of 1.0 mg kg−1 Maxy-G34 (PEG-G-CSF) at 24 ± 4h, two
doses at 24 ± 4h and d7–8, or three doses at 24 ± 4h, and d7–8 and d14–15 post irradiation
(filled bars); control mice were similarly injected but with vehicle (open bars). Thirty-day
survival was significantly increased for all G-CSF- or PEG-G-CSF-treated mice compared
to vehicle-treated controls. Bars represent mean ± SEM, * p≤0.05 comparing drug to vehicle
treated mice, n=212–221 mice per group (fig 1a), n=20 mice per group (fig 1b), and n=70–
110 mice per group (fig 1c).
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Fig. 2.
Survival of lethally-irradiated mice after administration of low doses of Maxy-G34 or
Neulasta. Mice were exposed to 8.7 Gy and injected subcutaneously with one dose of 0.1,
0.3, or 1.0 mg kg−1 Maxy-G34 (Fig. 2a, filled symbols) or Neulasta (Fig. 2b, filled symbols)
at 24 ± 4h post irradiation. Control mice were similarly injected but with vehicle at 24 ± 4h
post irradiation (open symbols, Fig. 2a and 2b). Thirty-day survival was significantly
increased for all mice treated with Maxy-G34 or Neulasta. * p<0.001 comparing drug to
vehicle treated mice, n=30 mice per group.
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Fig. 3.
CBC profiles in TBI-cont, TBI-G34 and non-TBI mice. At various times between 4 and 9mo
post-exposure, TBI-cont, TBI-G34 and non-TBI mice were assessed for peripheral white
blood cells (WBC, panel a), neutrophils (NE, panel b), lymphocytes (LY, panel c), red blood
cells (RBC, panel d) and platelets (PLT, panel e). Lines represent mean ± SEM. Data from
all time points were pooled for statistical analyses: † p<0.05 comparing non-TBI to TBI-
G34, ‡ p<0.05 comparing non-TBI to TBI-cont, * p<0.05 comparing TBI-G34 to TBI-cont.
n=2–3 mice per group per time point.
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Fig. 4.
Bone marrow (BM) cellularity and primitive hematopoietic phenotypes in TBI-cont, TBI-
G34 and non-TBI mice. TBI-cont, TBI-G34 and non-TBI mice were sacrificed between 4
and 9mo post-exposure and LDBM isolated. LDBM was enumerated and absolute numbers
of LDBM cells per mouse (BM cellularity) were calculated as previously described (Chua et
al. 2012) (panel a). The percentage of different primitive hematopoietic cell phenotypes was
determined by flow cytometry as described (Chua et al. 2012), and multiplied by BM
cellularity in panel a to give the absolute number of the different phenotypes per mouse. The
following data are shown: panel b, %Sca-1+ of lineage-negative (lin-) cells; panel c, the
%Sca-1+ckit+ of lin- cells; panel d, %KSL cells; panel e, the absolute number of KSL cells
per mouse; panel f, %KSLCD150+ cells; panel g, the %CD150+ cells within the KSL
population; panel h, the absolute number of KSLCD150+ cells. Lines represent mean ±
SEM. Data from all time points were pooled for statistical analyses: † p<0.01 comparing
non-TBI to TBI-G34, ‡ p<0.05 comparing non-TBI to TBI-cont, * p<0.05 comparing TBI-
G34 to TBI-cont. n=3 mice per group per time point.
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Fig. 5.
Hematopoietic and pre-B lymphoid progenitors in TBI-cont, TBI-G34 and non-TBI mouse
BM. 1.0 × 105 LDBM from TBI-cont, TBI-G34 and non-TBI mice isolated at 4 and 6mo
post-exposure was suspended in duplicate in 1 mL of methylcellulose media containing
muSCF, muIL-3, rhuIL-6 and rhuEPO (for hematopoietic progenitors), or in 1 mL of
methylcellulose media containing rhuIL-7 (for pre-B lymphoid colonies). Cells were
incubated in 100% humidified 5% C02 in air at 37°C and enumerated 13 days later for CFU-
GM, BFU-E and CFU-GEMM colonies, or 7 days later for pre-B lymphoid colonies. The
total number of CFU-GM, BFU-E, CFU-GEMM and pre-B lymphoid colonies per mouse
are shown in panels a, b, c, and d, respectively. Bars represent mean ± SEM. Data from all
time points were pooled for statistical analyses: † p<0.05 comparing non-TBI to TBI-G34, ‡
p<0.01 comparing non-TBI to TBI-cont. n=3 mice per group per time point.
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Fig. 6.
Long-term engraftment potential of TBI-cont, TBI-G34 and non-TBI HSC in competitive
transplantation assays. Lethally irradiated congenic murine recipients were transplanted with
150 KSLCD150+ cells isolated from TBI-cont, TBI-G34 or non-TBI donors, along with 1.0
× 105 LDBM competitor cells of congenic origin. Peripheral blood from tail-snips was
obtained from transplanted recipients at monthly intervals and was analyzed by flow
cytometry to determine donor chimerism using antibodies against CD45.1 and CD45.2.
Lines represent mean ± SEM donor chimerism at 6 months post-transplant. Data from all
time points were pooled for statistical analyses: † p<0.001 comparing non-TBI to TBI-G34,
‡ p<0.001 comparing non-TBI to TBI-cont. n=5–12 recipients per group per time point.
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Fig. 7.
Lineage reconstitution of TBI-cont, TBI-G34 and non-TBI HSC in competitive
transplantation assays. Mice transplanted with TBI-cont, TBI-G34 or non-TBI KSLCD150+
cells in Fig. 6 were assayed for donor-derived lineage reconstitution at 6 months post-
transplantation. Peripheral blood from tail snips was stained with fluorescently tagged
antibodies to CD45.1, CD45.2, CD4, CD8, B220 and Gr1, and analyzed by flow cytometry
for donor- or competitor-derived CD4+ and CD8+ T cells, B cells and granulocytes. Panel a,
b and c depict the lineage reconstitution of 150 KSLCD150+ cells from TBI-cont, TBI-G34
and non-TBI donors, respectively (expressed as a percentage of total TBI-cont, TBI-G34 or
non-TBI donors, respectively). There are no data at the 4 month time point in panel a and
only n=1 mouse in panel b at 4 months, since transplanted mice at these time points did not
exhibit high enough donor chimerism (0.05% donor-derived chimerism) to allow lineage
analysis. Panels d, e and f show the lineage reconstitution by the congenic competitor cells
(expressed as a percentage of total competitor cells) that were co-transplanted with
KSLCD150+ from TBI-cont, TBI-G34 and non-TBI donors, respectively, which acts as an
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internal standard for normal lineage reconstitution. Bars represent mean + SEM. Data from
all time points were pooled for statistical analyses: † p<0.05 comparing non-TBI to TBI-
G34, ‡ p<0.001 comparing non-TBI to TBI-cont. n=1–12 recipient mice per group per time
point.
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Fig. 8.
Cell cycle analysis of TBI-cont, TBI-G34 and non-TBI hematopoietic populations. TBI-
cont, TBI-G34 and non-TBI mice were sacrificed at various times between 4 to 9mo post-
exposure, and BM hematopoietic populations were analyzed by flow cytometry for cell
cycle position using the DNA stain DAPI. Panels a, b and c show the cell cycle status of
lineage-negative (lin-), KSL and KSLCD150+ cell populations, respectively. Bars represent
mean ± SEM. Data from all time points were pooled for statistical analyses: † p<0.05
comparing non-TBI to TBI-G34, ‡ p<0.05 comparing non-TBI to TBI-cont. n=1–3 mice per
group per time point.
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Table 1
Summary of individual H-ARS experiments presented in Figures 1 and 2.
Experiment Rad dose(Gy, LDXX/30 estimate) Group
%Survival
(# live/total)
06.2/3 7.96, LD50 16 doses Neupogen, days 1 to 16 93% (28/30)
06.2/3 7.96, LD50 16 doses vehicle, days 1 to 16 60% (18/30)
07.002 7.96, LD50 16 doses Neupogen, days 1 to 16 96% (25/26)
07.002 7.96, LD50 1 dose vehicle, day 1 53% (16/30)
07.003 7.96, LD50 16 doses Neupogen, days 1 to 16 96% (25/26)
07.003 7.96, LD50 1 dose vehicle, day 1 70% (21/30)
07.009 7.96, LD50 16 doses Neupogen, days 1 to 16 90% (27/30)
07.009 7.96, LD50 1 dose vehicle, day 3 80% (24/30)
07.010 7.96, LD50 16 doses Neupogen, days 1 to 16 83% (25/30)
07.010 7.96, LD50 11 dose vehicle, days 1 to 11 67% (20/30)
08.008 8.42, LD50 16 doses Neupogen, days 1 to 16 85% (17/20)
08.008 8.42, LD50 2 doses vehicle, days 1+7 55% (11/20)
11.219 8.53, LD50 16 doses Neupogen, days 1 to 16 65% (11/17)
11.219 8.53, LD50 16 doses vehicle, days 1 to 16 24% (4/17)
11.219 8.72, LD70 16 doses Neupogen, days 1 to 16 59% (10/17)
11.219 8.72, LD70 16 doses vehicle, days 1 to 16 0% (0/17)
11.219 9.04, LD90 16 doses Neupogen, days 1 to 16 13% (2/16)
11.219 9.04, LD90 16 doses vehicle, days 1 to 16 0% (0/17)
08.008 7.96, LD50 1 dose Neulasta, day 1 95% (19/20)
08.008 7.96, LD50 2 doses Neulasta, days 1+7 95% (19/20)
08.008 7.96, LD50 2 doses vehicle, days 1+7 55% (11/20)
08.001 7.76, LD50 2 doses G34, days 1+7 95% (19/20)
08.001 7.76, LD50 3 doses G34, days 1+7+14 95% (19/20)
08.001 7.76, LD50 3 doses vehicle, days 1+7+14 80% (16/20)
08.001 7.96, LD70 2 doses G34, days 1+7 75% (15/20)
08.001 7.96, LD70 3 doses G34, days 1+7+14 85% (17/20)
08.001 7.96, LD70 3 doses vehicle, days 1+7+14 55% (11/20)
11.201 7.96, LD70 1 dose G34, day 1 100% (30/30)
11.201 7.96, LD70 1 dose vehicle, day 1 73% (22/30)
11.201 7.96, LD70 2 doses G34, days 1+8 100% (30/30)
11.201 7.96, LD70 2 doses vehicle, days 1+8 83% (25/30)
11.201 7.96, LD70 3 doses G34, days 1+8+15 100% (30/30)
11.201 7.96, LD70 3 doses vehicle, days 1+8+15 70% (21/30)
11.215 8.06, LD70 1 dose G34, day 1 95% (19/20)
11.215 8.06, LD70 1 dose vehicle, day 1 85% (17/20)
11.215 8.06, LD70 2 doses G34, days 1+8 95% (19/20)
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Experiment Rad dose(Gy, LDXX/30 estimate) Group
%Survival
(# live/total)
11.215 8.06, LD70 2 doses vehicle, days 1+8 90% (18/20)
11.215 8.29, LD90 1 dose G34, day 1 100% (20/20)
11.215 8.29, LD90 1 dose vehicle, day 1 60% (12/20)
11.215 8.29, LD90 2 doses G34, days 1+8 90% (18/20)
11.215 8.29, LD90 2 doses vehicle, days 1+8 75% (15/20)
11.218 8.70, LD90 1 dose G34, 0.1 mg/kg, day 1 47% (14/30)
11.218 8.70, LD90 1 dose G34, 0.3 mg/kg, day 1 37% (11/30)
11.218 8.70, LD90 1 dose G34, 1.0 mg/kg, day 1 47% (14/30)
11.218 8.70, LD90 1 dose Neulasta, 0.1 mg/kg, day 1 57% (17/30)
11.218 8.70, LD90 1 dose Neulasta, 0.3 mg/kg, day 1 43% (13/30)
11.218 8.70, LD90 1 dose Neulasta, 1.0 mg/kg, day 1 47% (14/30)
11.218 8.70, LD90 1 dose vehicle, day 1 0% (0/30)
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Table 2
Mean Survival Time (MST) of decedent mice in Neupogen, Neulasta, and Maxy-G34 survival studies.
Growth factor Dose(ug kg−1 day−1)
Injections MSTa
(Days±SD)
Neupogenb 125.0 16 14.3 ± 3.7
Vehicle N/A 1–16c 17.6 ± 4.7
Neulastad 1.0
1 18.0e
2 13.0e
Vehicle N/A 2 19.4 ± 3.5
Maxy-G34f 1.0
1 12.0e
2 15.2 ± 3.7g
3 10.2 ± 2.6g
Vehicle N/A
1 21.9 ± 4.4
2 20.7 ± 3.2
3 17.1 ± 5.6
aAverage of all studies.
bSignificantly decreased compared to vehicle when the MST of all studies are compared (p<0.001).
cVaried between 1and 16 injections.
dStatistical analysis of MST could not be done since only one mouse died in the Neulasta-treated groups.
eNo SD, since only one mouse died in this group.
fSignificantly decreased compared to vehicle, when the MST of all Maxy-G34-treated groups were combined and compared to all vehicle groups
combined (p=0.001).
gSignificantly decreased compared to corresponding vehicle group (p≤0.01).
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Table 3
Mean Survival Time (MST) of decedent mice in Maxy-G34 and Neulasta dose reduction study
Growth factor Dose
(mg kg−1 day−1)
Injections MST
(Days)
Maxy-G34
0.1 1 17.6
0.3 1 14.3
1.0 1 14.8
Neulasta
0.1 1 16.3
0.3 1 15.5
1.0 1 15.8
Vehicle N/A 1 16.2
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